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For years scientists have suspected that the environment plays a role in neurodegenerative diseases such as 
Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. Mycotoxin fumonisin B
1
 (FB
1
) is produced 
by several Fusarium species, mainly by Fusarium verticilioides, which is one of the most common fungi 
associated with corn worldwide. Fumonisins are known to cause equine leukoencephalomalacia, a disease 
associated with the consumption of corn-based feeds contaminated with FB
1
. Here we have reported chronic 
experimental toxicosis in one-year-old carp (Cyprinus carpio L.) receiving feed containing 100 mg kg-1 
or 10 mg kg-1 of added FB
1
 for 42 days. We focused on fumonisin toxicity in the ﬁ sh brain. After staining 
with hemalaun-eosin, histology of the ﬁ sh brain revealed vacuolated, degenerate, or necrotic neural cells, 
scattered around damaged blood capillaries and in the periventricular area. These ﬁ ndings suggest that 
fumonisin, although it is a hydrophilic molecule, permeated the blood-brain barrier of young carp and had 
a toxic effect on neuronal cells.
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The old hypothesis that neurotoxins may play 
a role in neurodegenerative disorders has recently 
been reintroduced into the focus of scientiﬁ c interest. 
There is provocative evidence that environmental 
exposure to certain toxins may affect the development 
of neurodegenerative disorders such as Alzheimer’s 
disease, Parkinson’s disease, parkinsonian syndromes, 
amyotrophic lateral sclerosis, and multiple sclerosis. 
Recently published works support the cycad hypothesis 
for Guamanian amyotrophic lateral sclerosis/
parkinsonism dementia complex (ALS/PDC), based 
on the detection of [beta]-methylaminoalanine 
(BMAA) of cyanobacterial origin in cycad tissue (1). 
Some environmental factors (e.g. cigarette smoking, 
high serum cholesterol levels, infections, metals, 
industrial or other toxins) may trigger oxidation, 
inﬂ ammation, and disease processes, particularly 
in people with genetic susceptibility to Alzheimer 
disease (2-5). Administration of 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) induces selective 
damage of the substantia nigra dopaminergic cells 
and causes the parkinsonian syndrome (6).
Mycotoxins are secondary fungal metabolites 
associated with severe toxic effects to vertebrates. 
They are produced by many phytopathogenic and food 
spoilage fungi including the Aspergillus, Penicillium, 
Fusarium, and Alternaria species. Food and feed 
contamination with mycotoxins is a worldwide 
problem. Beside their toxic effects on other organ 
systems, mycotoxins are neurotoxins that can produce 
a wide spectrum of behavioral and cognitive changes, 
ataxia, and convulsions. Systemic administration of 
harmaline and oxotremorine produces motor tremor 
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in a variety of mammalian species (7, 8). Naturally 
occurring tremorogenic mycotoxins are synthesised by 
the Aspergillus, Penicillium, and Claviceps species.
Factors affecting the risk of toxin-induced 
neurodegenerative disorders include time and 
concentration in the organism, the ability to access 
the central nervous system, and the route by which 
a compound reaches the central nervous system 
or secondarily affects other organ systems leading 
to central nervous system disruption. The blood-
brain barrier (BBB), which controls the passage of 
substances from the blood into the brain and spinal 
cord, lets essential metabolites, such as oxygen and 
glucose, pass from the blood to the brain and central 
nervous system (CNS), but blocks most molecules 
that are more massive than approximately 500 Da. 
BBB works as a ﬁ lter, restricting access to many 
natural toxins, metals, antibodies, and biological 
complexes and, in many cases, actively removing 
these substances from the brain by energy-dependent 
efﬂ ux (9). Various factors and conditions can increase 
the permeability of BBB, including hypertension, 
hyperosmolarity, microwaves, radiation, infection, 
brain injury due to trauma, ischaemia, inﬂ ammation, 
pressure, and certain substances. Additionally, BBB is 
not fully formed at birth, which means that it is more 
permeable in young animals and humans (10, 11).
Fumonisins are toxins produced by the fungi 
Fusarium verticiloides, Fusarium proliferatum, and 
allied species under favourable conditions during 
infection of corn (12, 13). The most frequent and 
potent among them is fumonisin B1 (FB
1
). Fumonisins 
contained in grain disrupt the sphingolipid metabolism 
by inhibiting ceramide synthase, which in turn rapidly 
increases intracellular sphinganine concentration 
(14). The primary cause of toxicity seems to be the 
accumulation of sphingoid bases, but the effects also 
involve many other biochemical events (14, 15). In 
addition to naturally occurring toxicoses in several 
species such as leukoencephalomalacia in horses 
(16) or pulmonary oedema in swine (17), laboratory 
experiments have demonstrated sensitivity to FB
1
 in all 
tested animals. FB
1
 has a molecular weight of 705 Da 
and is a highly hydrophilic chemical. Following 
gavage administration, it poorly absorbs from the 
gastrointestinal tract; trace amounts were detected in 
urine, liver, kidney, and in red blood cells, whereas 
none was detected in plasma, heart, or brain. It does 
not appear to cross the placenta, and there is little 
evidence that it crosses BBB (18-20). 
The only ﬁ sh species tested so far, channel catﬁ sh 
(Ictalurus punctatus), were exclusively fed on diet 
contaminated with FB
1
 at concentrations of 35 mg 
kg-1, 62 mg kg-1, 170 mg kg-1, or 313 mg kg-1 for 
5 weeks (21). Here we have reported chronic 
experimental neurotoxicosis in one-year-old carp 
(Cyprinus carpio L.) receiving feed containing 
100 mg kg-1 or 10 mg kg-1 of added FB
1
 for 42 days. 
MATERIALS AND METHODS
Fumonisin B
1
Fumonisins were biosynthesisedin a liquid culture 
medium (yeast extract 20 g; sucrose 40 g; 1000 mL 
sterile water, pH 7.4) inoculated with a F. verticiloides 
isolate from a corn sample from Northern Croatia. 
One-millilitre suspension of conidia was inoculated 
into 1000 mL of the medium and incubated at 25 °C 
for 15 days. All chemicals (pro analysis) used for 
the extraction of FB
1
 were purchased from Kemika 
(Croatia). The F. verticiloides liquid culture medium 
was homogenised with a 100-mL acetonitrile:distilled 
water mixture (9:1) in an electric homogeniser (3500 
rpm) for 10 minutes and then ﬁ ltered. The ﬁ ltrate was 
extracted with n-hexane (2x25 mL) to remove lipids. 
The upper hexane phase of the ﬁ ltrate was removed 
and the water-soluble phase, adjusted to pH value 8 
to 9 with 25 mL NaHCO
3
 (saturated solution) was 
then shaken with 2x25 mL of chloroform. The water-
soluble phase was partially evaporated at 80 °C and 
then concentrated under vacuum by lyophilisation 
(Freeze dryer Alpha 1-4, Martin Chirst Osterode/
Harz). The lyophilisate (100 mg) was dissolved in 
water (100 mL). The water solution of the sample 
(50 µL) and 10 µL of FB
1
 standard (0.5 mg mL-1) 
(Sigma Chemical Co., approx 98 %) were spotted 
on preparative GF254 silica plates (Sigma Aldrich 
Chemie Gmbh) (20 cm x 20 cm), preheated for an 
hour to 110 °C. The plates were developed with 
acetonitrile:toluene:water (93:5:2) and subsequently 
dried in warm air. FB
1
 was visualised under 366 nm 
UV light as bright blue zones and identiﬁ ed by its 
retention factor (Rf) of 0.75. It was puriﬁ ed by thin 
layer chromatography (TLC). Different amounts 
of the lyophilisate water solution were spotted on 
preparative GF254 silica plates and developed with 
acetonitrile:toluene:water (93:5:2). The fumonisin 
was scraped from the plates, dissolved in water, 
ﬁ ltered to remove the silica gel, and the ﬁ ltrate was 
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lyophilised. This procedure was repeated to collect 
the necessary amount of FB
1
. A stock solution of FB
1
 
was prepared indistilled water (5 mg mL-1) and kept 
refrigerated at 4 °C. This stock solution was further 
diluted with distilled water for uniform admixing to 
the experimental feed.
Carp
Healthy one-year-old common carp (Cyprinus 
carpio L.) were obtained from a pond of the Topličica 
company (Novi Marof, Croatia). No obvious diseases 
or abnormalities were found by routine analyses before 
the experiment. The fish were randomly divided 
into four groups (mean weight in each group: 127 g; 
range: 70 g to 131 g) of eight ﬁ sh each and placed 
in four wire mesh cages (0.7 m x 0.7 m x 0.7 m) 
immersed in a pond. The experiment started after 4 
weeks of conditioning to the new environment and 
training to take manually given feed at or near the 
water surface.
Feed
Pellets were prepared weekly. Equal parts of 
crushed commercial pellets (PVA and Pellets Co., 
UK) for trout (protein content 45 %), wheat ﬂ our and 
an adequate amount of distilled water (with or without 
FB
1
) were mixed to obtain the dough. A household 
machine was modiﬁ ed toform pellets from the dough. 
After drying, the feed was stored in a refrigerator. 
The concentration of FB
1
 in the feed given to the 
experimental group I was 100 mg kg-1 of dry diet 
ingredients, and to group II 10 mg kg-1.
Measurement of Evans blue dye (EBD) for BBB 
integrity
The permeability of Evans blue dye was evaluated 
for BBB integrity in accordance with a modiﬁ ed 
method by Rapoport et al. (22). BBB integrity was 
measured in eight control animals not treated with 
FB
1
. The carp were anaesthetised with MS-222 (Sigma 
Aldrich Chemie Gmbh), and 2 mL kg-1 body weight 
of 2 % Evans blue dye saline (Sigma Aldrich Chemie 
Gmbh) was injected intracardially and allowed to 
circulate for a couple of minutes. The pericardial 
cavity of the carp was opened and perfused with 
saline solution through bulbus arteriosus, and then 
by 4 % formaldehyde in PBS. After the experiment, 
the anaesthetised carp were bled by cutting the gill 
arches. Their brains were removed immediately and 
post-ﬁ xed in 4 % formaldehyde in PBS solution. All 
brains were photographed (Fujiﬁ lm, FinePix A303, 
2x) and the degree of Evans blue staining graded on 
a scale of 0 to 3, according to the modiﬁ ed method by 
Rapoport et al. (22). Zero denoted no stain uptake, 1 
- light staining, 2 - darker staining, and 3 - deep blue 
staining.
Experimental procedure
The experiment started at the end of May and 
lasted 42 days. Mean water temperature during the 
experiment was (20±2.5) °C and the pH was 7 to 8. 
Three groups of ﬁ sh were receiving appropriate pellets 
(control, 10 mg kg-1 of FB
1
,
 
or 100 mg kg-1 of FB
1
) 
once a day in the amount equal to 5 % of their body 
weight. The fourth group was tested for BBB integrity 
with Evans blue dye. Once a week, the groups were 
examined visually by lifting the cages. We looked 
for dermal lesions, and followed ﬁ sh behavior and 
vigilance.
Histopathology
At the end of the 42-day fumonisin B
1
 administration, 
the animals were killed by overexposure to the 
anaesthetic MS-222 (Sigma Aldrich Chemie Gmbh) 
and resected. Samples of the brain were ﬁ xed in 10 % 
neutral buffered formalin (Kemika Ltd., Croatia). After 
ﬁ xation, the samples were automatically dehydrated 
(Reichert-Jung, histokinette 2000) in a series of 
ethanol solutions of increasing concentrations, and 
then impregnated in parafﬁ n (termed hell-paraﬁ n). 
Parafﬁ n blocks were cut to 5-μm thick slices using a 
microtome (Leitz 1512), and the slices were stained 
with haematoxylin and eosin according to the method 
of Lillie (23). Histological brain samples were 
examined under a light microscope (Olympus BH-2) 
at 200x to 700x magniﬁ cation.
The degree of brain oedema was graded from 0 to 
3, as follows: 0 - no oedema; 1 - slight oedema; 2 - 
moderate oedema; 3 - severe oedema. The grading was 
based of the generally accepted morphological criteria 
for cerebral oedema: pallor of myelin, distension of 
perivascular and pericellular spaces, a loose or sieve-
like appearance of myelinated areas, rarefaction of 
subpial spaces, vacuolar appearance of the neuropil, 
and pools of protein-rich ﬂ uid (24, 25).
In the brain tissue, we determined the number 
of apoptotic cells, degenerative lesions, and the 
occurrence of inﬂ ammatory changes. The number of 
apoptotic cells was recorded in 10 randomly selected 
ﬁ elds at 400x magniﬁ cation. Degenerative lesions 
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(hyaline and/or vacuolar degeneration, necrosis) 
were counted in 10 randomly selected ﬁ elds at 400x 
magniﬁ cation. Inﬂ ammatory cells was counted in 
three randomly selected ﬁ elds at 200x magniﬁ cation 
and graded from 0 to 3, according to the number of 
ﬁ elds affected.
Statistical analysis
The data were statistically analysed using SPSS® 
and Microsoft Excel® for Windows). The Kruskal-
Wallis and Jonckheere Terpstra test were used 
for within-group comparisons of apoptotic cells, 
degenerative lesions, and inflammatory changes. 
Difference at P<0.05 was considered signiﬁ cant.
RESULTS
Clinical signs
We have observed no mortality in either 
experimental group. The ﬁ nal examinaiton revealed 
slower body-weight gain in both FB
1
-exposed groups 
[(80±10) g per animal in the low-dose group and 
(81±5) g in the high-dose group] than in control 
(114±12) g. Furthermore, six of the eight ﬁ sh in the 
high-dose fumonisin group had carp erythrodermatitis, 
and the group was markedly less vagile than other 
groups. However, no other clinical differences were 
observed among the three experimental groups.
BBB integrity testing
In the fourth group used exclusively for BBB 
integrity testing, the brains of six carps showed no 
Evans blue staining (Figure 1). In two carp, the spinal 
cord showed grade 1 staining (Figure 2), but the other 
parts of the brain were clear. Evans blue binds to 
albumin in vivo; its absence from the brain (with an 
exception of circumventricular organs) suggests that 
BBB is impermeable to proteins. 
Histological examination
Five ﬁ sh treated with higher FB
1
 doses had a 
moderate (Figures 3 and 4), two a slight, and one 
severe brain oedema. The degree of brain edema 
differed signiﬁ cantly (P>0.05) from the group treated 
with lower FB
1
 doses and control group. In both four 
carp had a slight brain oedema, two moderate, and 
two none.
Figure 1  Brain of control carp shows no Evans blue 
staining.
Figure 2  Evans blue staining of the circumventricular structure 
in the caudal neurosecretory system (transparent 
arrow) of control carp
Figure 3  Brain tissue shows accumulation of glial cells (open 
arrow) and some degenerate neural cells (black 
arrow) with histological signs of perivascular 
oedema in carp receiving diet with 100 mg kg-1 FB
1
 
(magniﬁ cation 500x).
Figure 4  Meningeal  conges t ion  and oedema wi th 
lymphomononuclear cells (transparent arrow) in carp 
receiving diet with 100 mg kg-1 FB
1 
(magniﬁ cation 
400x).
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Apoptoses (Figure 5) varied in morphology from 
cell shrinks and chromatin condensation to apoptotic 
bodies. The mean number of apoptoses was (1.00±0.81) 
in the high-dose fumonisin group, (0.5±0.52) in the 
low-dose fumonisin group, and (0.1±0.31) in the 
control group. The difference between high-dose 
fumonisin group and low-dose fumonisin group and 
the difference between both treated groups and control 
was signiﬁ cant (P<0.05).
signs of inﬂ ammation. The control group showed no 
inﬂ ammation. Accumulation of inﬂ ammatory cells 
differed signiﬁ cantly between the groups (P<0.05).
DISCUSSION
Depending on animal species, FB
1
 can cause 
neurotoxicity, hepatotoxicity, nephrotoxicity, 
immunosuppression, developmental abnormalities, 
liver tumours, and other disorders (26). It can cause 
equine leukoencephalomalacia (27) and porcine 
pulmonary edema (28). Although FB
1
 is evidently 
neurotoxic for horses and ponies, only a few 
investigations conﬁ rm its neurotoxicity in other animal 
species (29, 30).
Our results have shown dose-dependent 
histopathological changes in the brain and brain 
vasculature of carp treated with FB
1
. They demonstrate 
the neurotoxicity of FB
1
, which got across BBB.
An earlier study of adult channel catfish has 
shown that fumonisin causes perivascular lymphocyte 
inﬁ ltration in the brain (31). Our investigation suggests 
that FB
1
 passed BBB in young carp. Previous ﬁ ndings 
indicate that the molecular weight of the compound 
plays an important role in its capability of crossing 
BBB, For example, albumin, with molecular weight 
of about 69,000 Da (32) did not get across BBB. 
Evans blue staining has shown only trace amounts of 
albumin in the grey matter of spinal cord of two ﬁ sh. 
This suggests that FB
1
 can probably pass BBB to a 
minor degree in lower vertebrate species, which calls 
for further investigation. This level of permeation may 
be more probable in young animals.
Even though our results indicate the transport 
of FB
1
 to carp brain, it still remains unclear which 
mechanisms are involved. However, results on 
mammals suggest that FB
1
 transport to the brain 
does not depend on multidrug transport system, 
in which P-glycoprotein plays a major role. This 
is supported by the ﬁ ndings of Sharma et al. (33), 
who demonstrated that knockout mice deﬁ cient in 
P-glycoprotein did not exhibit greater sensitivity to 
FB
1
. Osuchovski et al. (34) reported that pre-treatment 
with lipopolysaccharides increased BBB permeability 
and allowed fumonisin to enter the brain of female 
BALB/c mice. Other studies showed that ochratoxin A 
(OTA) induced biochemical changes and cytotoxicity 
in rat brain (35, 36). Some in vitro studies suggest 
that ionophoric mycotoxin beauvericin (BEA) may 
be neurotoxic (37). In addition to fumonisins and 
Figure 6  Haematoxylin-eosin staining of coronal brain sections 
shows damaged, irregular, and ruptured structure of 
the ependymal cell layer. Cerebrospinal ﬂ uid in these 
areas contains cell debris and lymphocytes. (Carp 
receiving diet with 100 mg kg-1 FB
1
; magniﬁ cation 
700x).
Figure 5  Detail of focal neuronal apoptosis (black arrow) 
and necrosis (transparent arrow) with glial 
reaction in carp receiving diet with 100 mg kg-1 FB
1
 
(magniﬁ cation 700x).
The mean number of degenerative cells was 
(1.7±1.49) in the high-dose fumonisin group (Figures 
3 and 6), (1.0±0.66) in the low-dose fumonisin group, 
and (0.2±0.42) in the control group (P<0.05).
Most of the ﬁ sh treated with higher fumonisin doses 
had a moderate accumulation of inﬂ ammatory cells, 
and one showed severe inﬂ ammation (Figures 4 and 
6). Other animals from this group showed no obvious 
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ochratoxin, Fusarium spp. can produce secondary 
toxic metabolites, the so-called emerging mycotoxins 
such as fusaproliferin, beauvericin, enniatins, and 
moniliformin (38). In other words, contamination 
with Fusarium mould could expose animals to several 
mycotoxin species at the same time.
Marcine et al. (39) showed that direct exposure 
of murine brain to FB
1
 results in neurotoxicity, 
characterised by biochemical and pathological 
changes. Intraventricular injection of FB
1
 in their 
study caused neurodegeneration, inhibition of de 
novo ceramide synthesis, stimulation of astrocytes, 
and upregulation of pro-inﬂ ammatory cytokines in 
the brain of BALB/C mice.
Kwon et al. (40) have shown that FB
1
 alters 
sphinganine (Sa) levels and myelin synthesis in the 
central nervous system of developing rats. FB1 seems 
to cause pathological changes in the brain function and 
morphology by impairing sphingolipid metabolism.
Studies of equine leukoencephalomalacia raise the 
question why horses are particularly susceptible to 
neurotoxic effects of fumonisin than pther investigated 
animals. This is more likely due to lower BBB 
permeability to fumonisin-like molecules in these 
animals than due to greater fumonisin absorption 
from the gastrointestinal tract in horses. Further 
investigations should shed more light on this issue.
Our investigation also touches upon possible 
neurological consequences of fumonisin exposure 
early in life. Due to its speciﬁ c mode of development, 
the central nervous system of a young animal is 
relatively unprotected and highly susceptible to 
damage, especially by environmental pollutants. 
Research conducted with several pollutants suggests 
that early-life exposure to chemicals, even at 
environmental levels can produce neurotoxic effects 
long after exposure (41). Our ﬁ ndings suggest that 
chronic environmental exposure in early life may play 
a major role in the development of neurodegenerative 
disorders later in life.
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Sažetak
NEUROTOKSIČNOST FUMONIZINA B
1
 U ŠARANSKE MLAĐI (Cyprinus carpio L.)
Odavno je poznato da okoliš ima važnu ulogu u razvoju neurodegenerativnih bolesti kao što su Alzheimerova 
i Parkinsonova bolest te multipla skleroza. Mikotoksin fumonizin B
1
 (FB
1
) tvori nekoliko vrsta Fusariuma, 
najčešće F. verticillioides, koja je najučestaliji kontaminant kukuruza. Ovaj mikotoksin odgovoran je za 
leukoencefalomalaciju konja, mula i magaradi povezanu s konzumacijom kukuruza kontaminiranog s FB
1
. 
U ovom su radu prikazani rezultati kronične eksperimentalne toksikoze mlađi šarana (Cyprinus carpio L.) 
koji su u hrani primali 100 mg kg-1 i 10 mg kg-1 FB
1
 tijekom 42 dana. Nakon bojenja hemalaun-eozinom 
zabilježene su značajne histopatološke promjene na mozgu životinja uključujući vakuolizaciju, degeneraciju 
i nekrozu neurona, posebice u blizini oštećenih krvnih kapilara i u periventrikularnoj regiji. Ova saznanja 
pokazuju da FB
1
, kao hidroﬁ lna molekula, prolazi kroz krvno-moždanu barijeru mladih šarana uzrokujući 
oštećenje neurona.
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